Wellington Discloses 6.2% Stake in Crinetics (CRNX) — 5.8M Shares
Wellington Management reporting persons disclose beneficial ownership of 5,807,308 shares of Crinetics Pharmaceuticals common stock, representing 6.2% of the class.
Rhea-AI Filing Summary
Wellington Management reporting persons disclose beneficial ownership of 5,807,308 shares of Crinetics Pharmaceuticals common stock, representing 6.2% of the class. The stake is reported across multiple Wellington entities (holding companies and investment advisers) and is held of record by clients of the Wellington investment advisers.
The filing shows no sole voting or dispositive power reported by the filers and reports shared voting power and shared dispositive power across the Wellington entities. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control.
Positive
- Institutional ownership of 5,807,308 shares (6.2%) demonstrates meaningful investor interest in CRNX
- Holdings are held in the ordinary course of business, with filers certifying they are not seeking to change control
Negative
- None.
Insights
TL;DR: An institutional investor group reports a passive, >5% position in CRNX (5.8M shares), indicating meaningful institutional interest.
Wellingtons collective ownership of 5,807,308 shares (6.2%) is a material, yet passive, holding and is recorded as owned of record by clients of its investment advisers. The absence of sole voting or dispositive power and the certification that holdings are in the ordinary course suggest this is not an activist or control-seeking position. For investors, this signals significant institutional conviction without immediate governance changes.
TL;DR: Multiple Wellington entities report shared voting/dispositive authority; the filing reflects coordinated reporting, not control intent.
The Schedule 13G discloses the structure of ownership across holding companies and investment-adviser entities, with several entities classified as HC (holding company) and at least one as IA (investment adviser). Reported shared voting and dispositive power—rather than sole control—combined with the ordinary-course certification, indicate reporting for regulatory transparency rather than a governance change. The filing clarifies which Wellington entities hold economic and voting interests.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which Wellington entities filed the Schedule 13G for CRNX?
Is Wellington seeking to influence control of Crinetics (CRNX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.